Business Restructuring / Divestment
Indoco Remedies Approves ₹110 Crore Slump Sale of Ophthalmic Business to Sunways India
NSE
indoco
BSE
532612
Indoco Remedies has approved and executed an agreement to sell its ophthalmic division across multiple geographies to Sunways (India) Pvt Ltd for ₹110 crore via slump sale, as part of its strategy to focus on core therapeutic areas
PRICE-SENSITIVE TRIGGER
Event: Slump Sale of Business Division
Type: Business Restructuring / Divestment
Impact: Neutral
Immediate Effect: Portfolio rationalisation improves strategic focus, but limited financial impact due to small revenue contribution
Key Metrics:
- Transaction Value: ₹110 crore
- Revenue Contribution (Divested Unit): ₹47.79 crore
- Contribution to Total Revenue: ~3.2%
Highlight:
- Low Impact Divestment: Non-core business with minimal revenue contribution
What Happened ?
Indoco Remedies has approved and executed an Agreement to Transfer Business (ATB) for the sale of its ophthalmic division across India and several African markets to Sunways (India) Private Limited.
The transaction is structured as a slump sale on a going concern basis and is expected to be completed within approximately three months, subject to conditions.
key highlights
Business Divested:
- Ophthalmic division (eye-care products)
- Covers territories:
- India
- Multiple African countries (Benin, Kenya, Tanzania, etc.)
- Sold as a going concern
Transaction Structure:
- Slump sale (transfer of entire business unit)
- Not executed via scheme of arrangement
- Does not qualify as “substantial undertaking” under Companies Act
- Not a related party transaction
Buyer Details:
- Buyer: Sunways (India) Pvt Ltd
- Independent third-party entity
- Not part of promoter group
Financial Relevance:
- Division contributes only ~3.2% of total revenue
- FY25 revenue contribution: ₹47.79 crore
- Limited impact on overall topline
Strategic Rationale:
- Focus on core therapeutic areas
- Exit from non-core business segment
- Improve capital allocation efficiency
- Streamline product portfolio
Timeline:
- Agreement executed: April 30, 2026
- Expected completion: ~3 months (subject to conditions)
Note:
Final closure depends on regulatory and contractual conditions
Risk Analysis
Key Risks
- Limited impact due to small business size
- Execution delays in transaction closure
- Potential loss of niche market presence in ophthalmology
- Reinvestment risk (deployment of ₹110 crore proceeds)
Worst Case Scenario
- If proceeds are not effectively reinvested, value creation from divestment may be limited
Risk Level: Low
Company Commentary
- Divestment aimed at focusing on core therapeutic areas
- Ophthalmic business classified as non-core
- No change in shareholding structure
- Transaction is arm’s length and non-related party
Official Exchange Filing: Indoco Remedies Limited